Audited financial result for the quarter and year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The company (now possibly renamed to Centuple Global Ltd, Scrip Code 531099) has filed audited results for FY2014-15, which show zero revenue from operations across all quarters and the full year. Total expenses stood at ₹7.48 lakhs for FY2015 versus ₹5.86 lakhs in FY2014, leading to a pre-tax loss of ₹7.48 lakhs. After accounting for extraordinary items of ₹300 lakhs (depletion of assets/write-offs), the net loss for FY2015 ballooned to ₹307.48 lakhs. The balance sheet shows severely eroded equity with reserves and surplus at negative ₹50.77 lakhs against share capital of ₹546.83 lakhs, and cash and bank balance of just ₹12.54 lakhs. The filing was submitted to BSE in December 2025, indicating a very significant delay. The auditor (Prakash Modi & Associates) issued a clean opinion without any qualifications or going-concern flag.
This filing reveals a non-operational company with no business revenue, mounting accumulated losses that have eroded most of its equity, and the large extraordinary write-off suggests management is cleaning up the balance sheet. For shareholders, this is a red flag — the stock trades on a BSE-listed shell with no active business, and the 10-year delay in filing raises serious governance concerns.